Notícias Replimune Group Inc - REPL | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Replimune Group Inc (REPL)
Replimune Group Inc (REPL) Notícias

Replimune Group Inc (REPL)

14,675

-0,255

( -1,71% )

Atualizado: 15:57:57

Atrasado por 15 minutos

Capacite seu portfólio: Discussões em tempo real e ideias de negociação acionáveis.

Replimune Announces Proposed Public Offering

Form 8-K - Current report

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Form S-8 - Securities to be offered to employees in employee benefit plans

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune to Present at Two Upcoming Investor Conferences

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições